Máire Quigley

Máire Quigley is currently the Director and Clinical Biomarker Lead at Cullinan Therapeutics, focusing on clinical biomarker initiatives for two phase I T cell engager molecules targeting autoimmune diseases and acute myeloid leukemia. Additionally, Máire serves as a GLG Network Member, providing subject matter expertise on cell and gene therapy. Previous roles include Director of the Clinical Donor Apheresis Program at CRISPR Therapeutics, where oversight spanned over 150 clinical grade apheresis products across global clinical programs. At Novartis Institutes for BioMedical Research, Máire led translational strategy development for CAR-T cell therapy Kymriah and improved process efficiencies within cell and gene therapies. Máire's research background includes fellowships and positions at prestigious institutions such as The Ragon Institute, Cardiff University, and the Vaccine Research Center at the National Institutes of Health. Máire holds a Ph.D. in Immunology from Karolinska Institutet and a B.Sc. in Biotechnology from the University of Galway, along with ongoing studies at Harvard Extension School.